May 17, 2012
The Editor-in-Chief has granted immediate free access to the articles below:
-
Blood consult: Therapeutic strategy and complications in the adolescent and young adult with acute lymphoblastic leukemia
-
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide
in previously untreated multiple myeloma
-
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and
prolonged progression-free survival
-
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis
-
Progression in smoldering Waldenstrӧm macroglobulinemia: long-term results
e-LETTERS
Most recent
ANNOUNCEMENTS
-
ASH Image Bank, Re-launched, Enhanced, and Free -
Announcing Blood 2.0 -
ASH launches Hematology Web Focus: a unique resource for clinicians -
Now available! ASH Self-Assessment Program Fourth Edition Standard (print with online access and online only) -
Blood now offers faster feedback through e-Letters -
Blood cited as one of the top 100 influential biology and medicine journals -
ASH’s alternative to NIH policy on public access
THREE MOST FREQUENTLY READ ARTICLES +more collections
